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Abstract
Though surgical biopsies provide direct access to tissue for genomic characterization of brain cancer, they are
invasive and pose significant clinical risks. Brain cancer management via blood-based liquid biopsies is a
minimally invasive alternative; however, the blood-brain barrier (BBB) restricts the release of brain
tumor-derived molecular biomarkers necessary for sensitive diagnosis.
Methods: A mouse glioblastoma multiforme (GBM) model was used to demonstrate the capability of focused
ultrasound (FUS)-enabled liquid biopsy (sonobiopsy) to improve the diagnostic sensitivity of brain
tumor-specific genetic mutations compared with conventional blood-based liquid biopsy. Furthermore, a pig
GBM model was developed to characterize the translational implications of sonobiopsy in humans. Magnetic
resonance imaging (MRI)-guided FUS sonication was performed in mice and pigs to locally enhance the BBB
permeability of the GBM tumor. Contrast-enhanced T1-weighted MR images were acquired to evaluate the
BBB permeability change. Blood was collected immediately after FUS sonication. Droplet digital PCR was used
to quantify the levels of brain tumor-specific genetic mutations in the circulating tumor DNA (ctDNA).
Histological staining was performed to evaluate the potential for off-target tissue damage by sonobiopsy.
Results: Sonobiopsy improved the detection sensitivity of EGFRvIII from 7.14% to 64.71% and TERT C228T
from 14.29% to 45.83% in the mouse GBM model. It also improved the diagnostic sensitivity of EGFRvIII from
28.57% to 100% and TERT C228T from 42.86% to 71.43% in the porcine GBM model.
Conclusion: Sonobiopsy disrupts the BBB at the spatially-targeted brain location, releases tumor-derived
DNA into the blood circulation, and enables timely collection of ctDNA. Converging evidence from both
mouse and pig GBM models strongly supports the clinical translation of sonobiopsy for the minimally invasive,
spatiotemporally-controlled, and sensitive molecular characterization of brain cancer.
Key words: Image-guided focused ultrasound, blood-brain barrier, blood-based liquid biopsy, glioblastoma mutation, droplet
digital PCR
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Introduction
Brain cancer severely threatens human health
due to their disruption of neurological function, poor
prognosis, and substantial reduction in quality of life
[1,2]. At present, patients with glioblastoma (GBM),
the most common primary brain tumor in adults,
have a median survival time of 14 months from the
time of diagnosis [3,4]. Genomic characterizations of
cancer are transforming clinical medicine, moving
from the current model of population risk assessment
and empirical treatment to individualized care based
on molecular classification and targeted therapy [5–8].
However, the lack of minimally invasive access to
brain tumor specimens for genomic analysis
precludes the molecular characterization of brain
cancer over time and hinders the development of
effective therapeutic approaches.
The two pillars of diagnostic management of
malignant brain tumors are neuroimaging and
surgically acquired tissue for pathology and genetic
profiling. Current diagnostic evaluation typically
relies on magnetic resonance imaging (MRI) and
computed tomography to identify suspicious tumor
lesions, followed by surgical resection or stereotactic
biopsy for histological confirmation and genetic
characterization. Because these procedures carry
surgical risk [9], tissue biopsies cannot be performed
for tumors at inoperable locations, or patients who are
too ill to tolerate invasive procedures [10]. Given the
dynamic nature of these aggressive tumors, a routine
interrogation to assess treatment response and cancer
recurrence is critically needed. Yet, repeated tissue
biopsies are often not feasible given the increased risk
for complications and morbidity. In addition, tissue
biopsies cannot capture the spatial heterogeneity
because the genetic analysis is typically performed for
a single tumor region [11].
Blood-based liquid biopsy (LBx) is a rapid and
inexpensive way of obtaining clinically relevant
information about the tumor without surgery [12]. It
is a promising approach for the diagnosis, molecular
characterization, and monitoring of brain cancer by
detecting circulating tumor-derived biomarkers, e.g.,
DNA, RNA, extracellular vesicles, and proteins shed
by tumors into the blood circulation [13–17].
Although blood-based LBx-guided personalized
therapy has already entered clinical practice for the
management of several cancers [18,19], limited
progress in the clinical use of blood-based LBx has
been achieved for brain cancer. One major challenge is
that the presence of brain tumor biomarkers in the
blood circulation is quite limited due to the
blood-brain barrier (BBB). The BBB is a unique
vascular structure in the brain that prevents molecules
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from non-selectively crossing between the circulating
blood and the extracellular fluid of the central
nervous system. The BBB protects neural tissues from
being exposed to toxins in the blood circulation, but it
also hinders the release of brain tumor-derived
molecular biomarkers into the bloodstream, resulting
in extremely low concentrations of circulating
biomarkers [20,21]. Though the vasculature of
gliomas is generally leaky, the tumor-associated BBB
permeability can be highly heterogeneous [22,23].
New vessels may maintain healthy BBB properties
and tumor cells may infiltrate the healthy
parenchyma where the BBB remains intact [24]. There
is a need to increase the BBB permeability to ensure
sufficient biomarker release for blood-based LBx
diagnosis. Circulating tumor DNA (ctDNA), which
carries information about the dynamics of
cancer-specific genetic and epigenetic alternations, is
currently the most well-studied and validated
biomarker for LBx. Although a number of
publications have demonstrated the ability to detect
ctDNA in patients with brain cancer, brain
tumor-derived ctDNA is generally detected at low
abundance and in a limited number of patients, which
makes analysis difficult in routine clinical practice
[15,21,25,26]. With advanced biomarker detection
techniques, ctDNA is detectable in >75% of patients
with advanced pancreatic, ovarian, colorectal bladder,
melanoma, and head and neck cancer, but is
detectable in <10% of glioma patients [21]. Current
strategies all focus on developing advanced, highly
sensitive biomarker detection techniques for
analyzing the collected specimens, such as droplet
digital PCR (ddPCR) [27], optimized next-generation
sequencing (NGS) [28], and advanced spectroscopy
[29]. While these techniques are critical in improving
sensitivity to the presence of these sparse circulating
biomarkers, there is a critical need of techniques that
overcome the biophysical barrier that is responsible
for this sparsity.
We developed the "sonobiopsy" technique to
advance the diagnosis of brain cancer. Sonobiopsy
uses focused ultrasound (FUS) in combination with
microbubbles to disrupt the BBB and enhance the
release of tumor-derived biomarkers from the
FUS-targeted brain location into the blood circulation.
FUS has the potential to target any area in the whole
brain with high precision (on the order of millimeter)
in animal models and humans. FUS combined with
microbubbles is known to transiently and locally
disrupt the BBB [30–33] for improved brain drug
delivery in preclinical tumor models [34–36] and
non-tumor studies [37–43] and clinical trials
[38,44,45]. We introduced the hypothesis that
FUS-induced BBB disruption enables "two-way
https://www.thno.org
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trafficking" between the brain and bloodstream [46–
48]. While circulating agents can be allowed to enter
the brain using FUS-mediated BBB disruption, brain
tumor-derived biomarkers can also be released into
the blood circulation to improve the sensitivity of
blood-based LBx. Sonobiopsy enables spatiotemporally-controlled biomarker detection, which
cannot be achieved by conventional blood-based LBx.
Blood LBx can reflect the global molecular status, i.e.,
coexistence of different genotypic profiles, but cannot
provide spatially-precise genetic information [49,50].
On the other hand, sonobiopsy can release brain
tumor-specific biomarkers from precisely defined
tumor locations to identify the molecular profile
unique to the target site. Meanwhile, many tumor
biomarkers have short half-lives in the blood, on the
order of 16 minutes to 2.5 hours for ctDNA, due to
clearance [51]. The blood samples can be collected
immediately after the FUS-induced biomarker release,
which should minimize the clearance.
Several proof-of-concept studies have shown the
feasibility of sonobiopsy to enhance biomarker release
from the brain to the blood. Our previous study has
proven the concept that sonobiopsy enriched blood
specimens with enhanced green fluorescent protein
(eGFP) mRNA using GBM mouse models established
by the direct implantation of eGFP-transduced
glioblastoma cells into the mouse brain [47]. We also
showed that sonobiopsy enhanced the release of two
brain-specific protein biomarkers (glial fibrillary
acidic protein and myelin basic protein) using a
healthy pig model [48]. By retrospectively analyzing
blood samples collected from FUS-mediated drug
delivery clinical trials, Meng et al. provided
preliminary clinical evidence that FUS-induced BBB
disruption increased the concentrations of circulating
biomarkers
(cell-free
DNA,
neuron-derived
extracellular vesicles, and brain-specific protein) [52].
Although promising, there is a lack of compelling
evidence that demonstrates the capability of
sonobiopsy in improving the diagnostic sensitivity of
brain tumor-specific genetic mutations compared
with conventional blood-based LBx. Meng et al.
detected IDH1-R132H mutation in one patient, who
was known to harbor the tumor mutation. However,
this did not address the critical question of whether
sonobiopsy could enhance the sensitivity in the
detection of tumor mutations, which was the goal of
our study. This evidence is critically needed to
support the clinical application of sonobiopsy.
Over the past decade, large-scale DNA
sequencing efforts have identified several key
genomic alterations for various brain cancers. Since
the 2016 World Health Organization classification, the
routine diagnostic workup for GBM requires genetic
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analysis of tissue samples to guide patients’ prognosis
stratification
and
treatment
decisions
[53].
Specifically, GBM frequently harbors the epidermal
growth factor receptor mutation variant, EGFRvIII
[54,55], and the telomerase reverse transcriptase
promoter mutation, TERT C228T [16]. The EGFRvIII
mutation occurs in 30–40% of GBM patients and
represents an aggressive subtype of GBM [56–58]. The
sensitive characterization of an EGFRvIII-positive
tumor may inform personalized drug trials where
some agents may outperform other drugs [59]. TERT
promoter mutations occur in 62% of GBM patients
and are associated with poor treatment outcome
[16,60]. This association may enable variants, such as
TERT C228T, to be a prognostic biomarker for clinical
outcome. Blood-based liquid biopsies have shown
promise in detecting glioma-specific alterations, such
as EGFRvIII and TERT C228T, for molecular
classification of tumors. However, the low detection
sensitivity of current assays limits the positive
predictive value [61]. In this study, we demonstrated
that sonobiopsy significantly improved the sensitivity
in the detection of EGFRvIII and TERT C228T
mutations in ctDNA compared with conventional
blood-based LBx using a mouse model of GBM. As
the mouse model cannot represent the technical
challenge of FUS delivery through the thick human
skull, and biomarkers released by sonobiopsy will be
far more diluted in humans than in mice, there is a
need to develop a large animal model of GBM to
characterize the translational implications in humans.
We developed a porcine model of GBM and
quantified the sensitivity of sonobiopsy in ctDNA
mutation detection. Our study showed, for the first
time, that sonobiopsy improved the sensitivity in the
detection of two tumor-specific mutations in mouse
and porcine models of GBM. This work provides
convincing evidence that sonobiopsy can achieve
minimally invasive, spatiotemporally-controlled, and
sensitive detection of GBM mutations.

Results
Sonobiopsy enhanced detection of brain
tumor-specific mutations in a mouse GBM
model
Human GBM cells (U87) with EGFRvIII
overexpression (U87-EGFRvIII+) and carrying TERT
C228T mutation were used to establish the mouse
model of GBM. This model was used to compare the
detection of EGFRvIII and TERT C228T mutations
with sonobiopsy or conventional blood-based LBx
(blood LBx). A commercially available MRIcompatible FUS system (Image Guided Therapy,
Pessac, France) was set up in a small animal MRI
https://www.thno.org
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scanner (Figure 1A). Approximately 10–12 days after
intracranial implantation, the mice were assigned to
blood LBx (collect blood without FUS) or sonobiopsy
(collect blood immediately after FUS). The average
tumor volumes for the blood LBx (n = 21) group and
the sonobiopsy group (n = 24) were not significantly
different (p = 0.78; unpaired two-sample Wilcoxon
signed rank test) at 25.11 ± 16.25 mm3 and 24.59 ±
13.21 mm3, respectively. The FUS parameters (FUS
pressure and microbubble dose) and post-FUS blood
collection time were optimized in a prior parameter
optimization study (Supplementary Figure S1).
Contrast-enhanced (CE) T1-weighted MRI scans
(Figure 1B) were acquired to assess tumor growth and
evaluate FUS-induced BBB disruption. FUS
significantly increased the volume of tissue with
enhanced BBB permeability by approximately 2-fold
on average (Figure 1C).
Terminal blood collection via cardiac puncture
was performed 10 minutes after FUS sonication.
Analysis of the plasma cell-free DNA (cfDNA) found
that sonobiopsy enhanced the release of cfDNA
compared to conventional blood LBx (Supplementary
Figure S2A). The plasma levels of mononucleosomal
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cfDNA
(140–230
bp)
[51,62–65]
increased
approximately
2-fold
with
sonobiopsy
(Supplementary Figure S2B). Custom ddPCR
primers and probes for the detection of EGFRvIII and
TERT C228T mutations were validated in vitro with
cell lines that have known mutation statuses
(Supplementary Figure S3). The 1D amplitude plots
show the detection of EGFRvIII for 8 representative
subjects in the blood LBx and sonobiopsy groups
(Figure 2A). The EGFRvIII ctDNA level in the
sonobiopsy group was significantly greater (920-fold)
than the blood LBx group (Figure 2B). The 1D
amplitude plots show the detection of TERT C228T
for 8 representative subjects in the blood LBx and
sonobiopsy groups (Figure 2C). There was a
significant increase (10-fold) in the levels of TERT
C228T ctDNA with sonobiopsy compared with blood
LBx (Figure 2D). Sonobiopsy improved the diagnostic
sensitivity from 7.14% to 64.71% for EGFRvIII and
from 14.29% to 45.83% for TERT C228T (Figure 2E).
The sensitivity with 95% confidence interval is shown
in Supplementary Table S1. Taken together,
sonobiopsy significantly enhanced the detection of
brain tumor-specific mutations.

Figure 1. FUS-induced BBB disruption verified by contrast-enhanced T1-weighted MRI scans. (A) Hardware setup for MRI-guided sonobiopsy in mice. The FUS transducer was
coupled with the mouse head using ultrasound gel and a bladder filled with degassed water. (B) Contrast-enhanced (CE) T1-weighted MRI scans were acquired before FUS to
quantify the tumor volume (blue area). Post-FUS MRI scans confirmed FUS-induced BBB disruption (orange area) as an increase in CE volume. (C) FUS significantly increased the
CE volume (n = 19, p = 0.0000038; ****p < 0.0001; paired samples Wilcoxon signed rank test) from 24.59 ± 13.21 mm3 to 46.09 ± 20.44 mm3. Black bars indicate mean in C.

https://www.thno.org
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Figure 2. Sonobiopsy increased the sensitivity of EGFRvIII and TERT C228T mutation detections in mouse plasma by ddPCR. (A) 1D amplitude plots for blood LBx and
sonobiopsy groups demonstrate the detection of EGFRvIII in plasma for each representative subject. The pink line depicts the threshold fluorescence for identifying droplets with
positive EGFRvIII expression. (B) The level in the sonobiopsy group (n = 17; 19.06 ± 24.74 copies/µL) was significantly greater (p = 0.00089; ***p < 0.001; unpaired two-sample
Wilcoxon signed rank test) compared with the level in the blood LBx group (n = 14; 0.02 ± 0.08 copies/µL). (C) 1D amplitude plots for the detection of TERT C228T in plasma
for each representative subject in the blood LBx and sonobiopsy groups. The pink line depicts the threshold fluorescence for identifying droplets with positive TERT C228T
expression. (D) FUS significantly increased the levels of TERT C228T ctDNA in the plasma from 0.06 ± 0.18 copies/µL in the blood LBx group (n = 21) to 0.64 ± 1.19 copies/µL
in the sonobiopsy group (n = 24; p = 0.015; *p < 0.01; unpaired two-sample Wilcoxon signed rank test). (E) With ddPCR, sonobiopsy is more sensitive than blood LBx with a
detection rate of 64.71% for EGFRvIII and 45.83% for TERT C228T compared with 7.14% and 14.29% for blood LBx, respectively. ND: not detected. Black bars indicate mean
in B and D.

No significant off-target tissue damage by
sonobiopsy in mouse GBM model
One safety concern with sonobiopsy was the
potential for tissue damage in the parenchyma. H&E
staining was performed to quantify the extent of
FUS-induced microhemorrhage and TUNEL staining
was used to evaluate the number of apoptotic cells.
Sonobiopsy led to a non-significant increase in
detected microhemorrhage within the tumor region of
interest (ROI) (Figure 3A-B). There was no off-target
damage in the brain parenchyma. Sonobiopsy also did

not change the TUNEL expression in the tumor ROI
or the brain parenchyma (Figure 3C-D).

Sonobiopsy enhanced detection of brain
tumor-specific mutations in a porcine GBM
model
To validate the clinical translatability of
sonobiopsy to enhance the detection of brain
tumor-specific mutations, a porcine model of GBM
was developed. This model was comprised of a
bilateral implantation of the same U87-EGFRvIII+ cells
as the mouse model in the pig cortex followed by
https://www.thno.org
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immunosuppressant treatment to prevent rejection of
the grafted cells [66,67]. The bilateral tumor model
capitalized on the unique feature of the large brain
volume in pigs and provided the opportunity for
sonobiopsy to target two distinct targets in individual
pigs. Sonobiopsy was performed approximately 11
days after intracranial implantation. A customized
MRI-guided FUS device was developed to sonicate
each large animal tumor sequentially (1 hour delay to
minimize cross-contamination from biomarker release
of the first sonication) in a clinical MRI scanner [48]
(Figure 4A-B). Contrast-enhanced T1-weighted MRI
scans confirmed successful BBB disruption of both
tumors (Figure 4C), where the total CE volume
significantly increased post-FUS (Figure 4D).
Blood samples (5 mL) were collected
immediately before and 10 minutes after FUS
sonication of each tumor. The ddPCR 1D amplitude
plots demonstrate the detection of EGFRvIII for all
subjects in the blood LBx (pre-FUS) and sonobiopsy
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(post-FUS) groups (Figure 5A). Sonobiopsy
significantly enhanced the release of EGFRvIII ctDNA
into the blood by 270-fold (Figure 5B). The 1D
fluorescence amplitude plots show the detection of
TERT C228T with ddPCR for all subjects in the blood
LBx and sonobiopsy groups (Figure 5C). The levels of
TERT C228T ctDNA significantly increased 9-fold
with sonobiopsy (Figure 5D). The sonobiopsyinduced release improved the diagnostic sensitivity
from 28.57% to 100% for EGFRvIII and from 42.86% to
71.43% for TERT C228T (Figure 5E). The sensitivity
with 95% confidence interval is shown in
Supplementary Table S1. Sonobiopsy was shown to
significantly enhance the detection of brain
tumor-specific mutations in a pig GBM model.

No significant tissue damage by sonobiopsy in
pig GBM model
The safety risks associated with large animal
sonobiopsy were evaluated by histological staining
with H&E and TUNEL. H&E staining shows the
presence of microhemorrhage near the edge of the
tumor in some cases (Figure 6A). However, there was
no significant difference in microhemorrhage density
between the sonicated tumor ROI and the
unsonicated parenchyma (Figure 6B). In addition, the
TUNEL staining (Figure 6C) suggests there was no
significant difference between the number of
apoptotic cells in the parenchyma compared with the
tumor ROI (Figure 6D). MRI was used to evaluate
acute tissue damage post-FUS. Abnormalities in the
post-FUS T2*-weighted images, i.e., signal intensity
changes, were observed (Supplementary Figure S4B).
The observed tissue damage was consistent with the
reversible damage observed in clinical trials of
FUS-induced BBB disruption for brain drug delivery
[45,68,69].

Discussion

Figure 3. Sonobiopsy did not cause significant acute damage. (A) Representative H&E
staining for a subject treated with sonobiopsy. The red arrow points to
microhemorrhage in the tumor ROI. (B) The microhemorrhage density in the
parenchyma after sonobiopsy (0.47 ± 0.68 positive pixels/µm2, n = 5) was not
significantly different compared with that after blood LBx (0.83 ± 0.69 positive
pixels/µm2; n = 5, p = 0.33; unpaired two-sample Wilcoxon signed rank test). There
was a nonsignificant increase in microhemorrhage occurrence in the tumor ROI after
sonobiopsy (4.54 ± 3.08 positive pixels/µm2, n = 5) compared with that after blood
LBx (2.08 ± 3.54 positive pixels/µm2; n = 5, p = 0.18; unpaired two-sample Wilcoxon
signed rank test). (C) Representative TUNEL staining for a subject treated with
sonobiopsy depicts increased apoptotic signal in the tumor ROI. The black arrow
points to an apoptotic cell. (D) There was no significant difference in TUNEL density
for the parenchyma between blood LBx (0.20×10-3 ± 0.22×10-3 positive cells/µm2, n =
5) and sonobiopsy (0.47×10-3 ± 0.22×10-3 positive cells/µm2; n = 5, p = 0.11; unpaired
two-sample Wilcoxon signed rank test). There was no significant difference in
TUNEL density for the tumor ROI between blood LBx (1.82×10-3 ± 0.62×10-3
positive cells/µm2, n = 5) and sonobiopsy (1.97×10-3 ± 1.22×10-3 positive cells/µm2; n
= 5, p = 0.73; unpaired two-sample Wilcoxon signed rank test). Black bars indicate
mean in B and D.

This study showed that sonobiopsy enriched the
plasma ctDNA and improved the detection sensitivity
of two GBM mutations without posing significant
safety risks. Findings from this study provide
convincing evidence from small and large animal
models of GBM that supports the clinical translation
of sonobiopsy for spatially targeted and temporally
controlled detection of ctDNA. Further, this study
suggests that sonobiopsy does not pose a clinical risk
for significant microhemorrhage or increase in
apoptotic cells.
Sonobiopsy
addresses
the
fundamental
challenge of obtaining specimens for the sensitive
diagnosis and molecular characterization of brain
cancer. Sonobiopsy improved the plasma levels of
EGFRvIII ctDNA (920- and 270-fold increases for mice
https://www.thno.org
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and pigs, respectively) and TERT C228T ctDNA (10and 9-fold increases for mice and pigs, respectively).
Sonobiopsy achieved higher detection rates than
conventional blood LBx for EGFRvIII (increased the
detection sensitivity by 57.57% for mice and 71.43%
for pigs) and TERT C228T (increased by 31.54% for
mice and 28.57% for pigs). The enhanced plasma
levels and detection rate of EGFRvIII are striking
compared to those of TERT C228T. This discrepancy
may be attributed to the overexpression of the
EGFRvIII mutation in the U87-EGFRvIII+ cell line. On
the other hand, TERT C228T was only expressed on a
single chromosome. As a result, the EGFRvIII
biomarkers may experience a larger accumulation
during tumor growth and greater release after
FUS-mediated BBB disruption compared with TERT
C228T biomarkers. By using two biomarkers to
represent two different gene mutation expression
levels, this study demonstrated the range of potential
for sonobiopsy.
This study obtained convincing evidence from
both small and large animal models that supports the
clinical translation of sonobiopsy. The mouse models,
while well-characterized and common due to their
ease of genetic manipulation, short breeding times,
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and evolutionary similarities, lack a gyrencephalic
structure and other human-like features that are
relevant for sonobiopsy, such as skull thickness, brain
volume, and blood volume [70,71]. Therefore, the
results from the mouse experiments in this study
demonstrate the feasibility for improving the
detection sensitivity of mutations in ctDNA, but this
may not be clinically meaningful. A clinically relevant
large animal GBM model would corroborate the
conclusion. The spontaneous canine glioma model is
an option that has similar tumor initiation and
progression as humans in a comparable brain size
[70,72]. However, the tumor incidence is low and the
wide variation in size and location limit the
reproducibility of the tumor. A GBM model in
immunosuppressed cats has been developed, but the
unpredictable tumor growth, small brain size, and
unique brain vasculature limit its value in preclinical
studies [67]. The pig model is unique for its
human-like brain size, anatomy, and vasculature. In
addition, pigs are less expensive and pose less ethical
concerns than a non-human primate [67]. However,
only one group in the world had reported successful
development of a pig GBM model [66,67], which may
be due to technical challenges in adapting existing

Figure 4. FUS disrupted the BBB in a pig GBM model. (A) Hardware setup for MRI-guided sonobiopsy in pigs. The pig head was stabilized by the head supports. The
MR-compatible motor enabled the translation of the FUS transducer to specific target locations. (B) Placement of pig in sonobiopsy device. (C) CE T1-weighted MRI scan shows
tumor volume (blue area) and FUS-induced BBB disruption (orange area). (D) The CE volume significantly increased (n = 6; p = 0.031; *p < 0.05; paired samples Wilcoxon
signed rank test) from 348.70 ± 358.02 mm3 to 799.50 ± 501.19 mm3. Black bars indicate mean in D.

https://www.thno.org
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stereotactic devices for tumor cell implantation in the
pig brain, the difficulty in achieving adequate
immunosuppression, as well as the associated high
cost for the surgery and animal care. We overcame
these challenges and developed the pig GBM model
using our custom U87 cell line. Data obtained using
the pig GBM model provide convincing evidence that
sonobiopsy improved the sensitivity for the detection
of EGFRvIII and TERT C228T mutations in ctDNA
compared with conventional blood-based LBx. By
utilizing two species of different blood volumes, it is
possible to extrapolate for the clinical application of
sonobiopsy for detecting tumor mutations. In mice,
sonobiopsy enhanced the release of EGFRvIII ctDNA
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by 920-fold and the release of TERT C228T ctDNA by
10-fold when approximately 30% of the total blood
volume was collected (0.5 mL collected from 1.7 mL
total). In pigs where approximately 5% of the total
blood volume (30 mL collected from 620 mL total)
was collected, sonobiopsy enhanced the release of
EGFRvIII ctDNA by 270-fold and the release of TERT
C228T ctDNA by 9-fold. In humans, approximately
1% of the total blood volume can be collected (50 mL
collected from 5000 mL total). Assuming linearity
between fold change and the fraction of total blood
volume collected, it is estimated that sonobiopsy may
increase the release of EGFRvIII ctDNA by 212-fold
and TERT C228T ctDNA by 8.5-fold.

Figure 5. Sonobiopsy increased the sensitivity of EGFRvIII and TERT C228T mutation detections in pig plasma by ddPCR. (A) 1D amplitude plots for EGFRvIII detection in plasma
for each subject. (B) Sonobiopsy significantly increased plasma levels of EGFRvIII ctDNA (n = 7; p = 0.016; *p < 0.05; paired samples Wilcoxon signed rank test) from 13.69 ± 28.62
copies/mL to 3697.54 ± 3780.61 copies/mL. (C) 1D amplitude plots for TERT C228T detection in plasma for each subject. (D) Sonobiopsy significantly increased the plasma levels
of TERT C228T ctDNA (n = 10; p = 0.022; *p < 0.05; paired samples Wilcoxon signed rank test) from 13.07 ± 23.08 copies/mL to 112.25 ± 150.75 copies/mL. (E) With ddPCR,
sonobiopsy is more sensitive than blood LBx with a detection rate of 100% for EGFRvIII and 71.43% for TERT C228T compared with 28.57% and 42.86% for blood LBx,
respectively. ND: not detected. Black bars indicate mean in B and D.
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Figure 6. Histological analysis shows no significant tissue damage in pig GBM model.
(A) Representative horizontal slice with H&E staining. The microhemorrhage occurs
in some cases near the edge of the tumor (red arrows). (B) Microhemorrhage density
was not significantly different between parenchyma (0.33 ± 0.13 positive pixels/µm2, n
= 4) and tumor (1.28 ± 0.79 positive cells/µm2, n = 4, p = 0.20; unpaired two-sample
Wilcoxon signed rank test). (C) Representative TUNEL staining depicts the apoptotic
cells (black arrows). (D) There was no significant difference between the TUNEL
density in the tumor (110.40×10-4 ± 112.25×10-4 positive cells/µm2, n = 4) compared
with that in the parenchyma (51.34×10-4 ± 56.12×10-4 positive cells/µm2; (n = 4, p =
0.55; unpaired two-sample Wilcoxon signed rank test). Black bars indicate mean in B
and D.

The integration of sonobiopsy with advanced
blood analysis assays has the promise to provide
minimally invasive, spatiotemporal-controlled, and
sensitive diagnosis of brain cancer. Compared to
completely noninvasive technology for detecting
circulating markers in vivo [73], sonobiopsy is
minimally invasive because it requires venipuncture
for intravenous delivery of microbubbles and blood
collection. ddPCR is a targeted approach to rapidly
detect specific known mutations with high sensitivity
and high tissue concordance [74–76]. Thus, ddPCR
was used in our study to detect ctDNA with a priori
knowledge of the mutations expressed by the
implanted GBM tumors. This assisted in the sensitive
detection of mutant ctDNA with specific ddPCR
probes. In the clinic, this information may not be
known, e.g., if sonobiopsy is performed prior to
surgical biopsy or if the tumor evolves over time.
Thus, future studies will examine the molecular
landscape independent of hotspot mutations with
approaches such as whole genome sequencing,
next-generation sequencing, or bisulfite sequencing.
The advancements of these detection techniques have
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been improving the sensitivity of blood-based LBx.
For example, Nassiri et al. demonstrated that the
sensitivity
of
blood-based
LBx
to
detect
glioma-derived ctDNA may improve with cfDNA
methylation analysis [13]. Despite the advancements
in the detection techniques, sonobiopsy provides
spatially targeted and temporally controlled sample
collection that conventional blood-based LBx cannot
offer. When a blood sample is drawn during
blood-based LBx, the spatial heterogeneity of the
tumor cannot be resolved. However, FUS precisely
delivers acoustic energy to a discrete target with a
high lateral resolution. The BBB disruption that
releases biomarkers are confined within that location.
Therefore, sonobiopsy has the potential to provide
more granularity in characterizing the tumor
heterogeneity by targeting different tumor sites and
identifying the molecular profile unique to each
spatial location [11,17,77]. Meanwhile, the level of
circulating biomarkers is determined by a balance
between biomarker release and clearance processes
[78,79]. Sonobiopsy can not only enrich the
concentration of circulating biomarkers, but also
minimize the effect of clearance by collecting the
blood samples immediately after biomarker release.
Sonobiopsy did not pose significant safety risks.
Although not statistically significant, the average
microhemorrhage and TUNEL densities were higher
in the tumor after sonobiopsy than the control group.
There was a trend for the pigs where the average
microhemorrhage density was higher in the tumor
than the parenchyma. In addition, hypointensities
that indicate microhemorrhages were observed in the
post-FUS T2*-weighted MR images for pigs. This
evidence indicated that FUS-mediated BBB disruption
led to tissue damage in the FUS-targeted region with
minimal off-target effects in the parenchyma outside
the FUS-targeted region. FUS-induced tissue damage
has been reported in previous studies where the
abnormalities recovered within 4 days in mice [80]
and within 1-2 months in humans [68,69]. In addition,
Meng et al., who published the retrospective study on
MR-guided focused ultrasound liquid biopsy
observed similar damage during the clinical study
that was resolved within 24 hours [45]. It is not
expected that sonobiopsy would contribute to GBM
metastasis. Brain tumors, such as GBM, grow locally
and rarely metastasize outside the central nervous
system (incident rate: 0.4-0.5%) [14,21,81,82]. There
have not been any documented cases of metastasis or
release of tumor cells in preclinical and clinical studies
of FUS-induced BBB disruption. This may be the case
because existing assays have low sensitivities
compared with advanced techniques that have been
developed for the purpose of detecting circulating
https://www.thno.org
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tumor cells [83,84]. Regardless, the release of tumor
cells is not likely because FUS is less invasive than
invasive procedures, e.g., needle biopsy and laser
treatment, which could increase the circulating tumor
cells [85]. Future studies will be performed to validate
the long-term safety of sonobiopsy.
We analyzed the correlations between biomarker
release, contrast enhancement, and tissue damage.
There was no strong correlation observed in the
mouse experiment between microhemorrhage density
and EGFRvIII ctDNA plasma level (n = 5, Pearson's
correlation coefficient r = 0.12, p = 0.72),
microhemorrhage density and change in CE volume
(n = 5, r = 0.025, p = 0.96), or EGFRvIII ctDNA plasma
level and change in CE volume (n = 17, r = 0.13, p =
0.66). Further, there was no strong correlation
observed in the pig experiment between
microhemorrhage density and change in EGFRvIII
ctDNA plasma level (n = 4, r = -0.74, p = 0.26),
microhemorrhage density and change in CE volume
(n = 4, r = -0.62, p = 0.38), or change in EGFRvIII
ctDNA plasma level and change in CE volume (n = 6,
r = -0.43, p = 0.29). The lack of a strong correlation
suggests that FUS-induced biomarker release is a
complex process that may be affected by many
variables and/or a larger sample size is needed to
detect these correlations.
Besides neuroimaging and surgically acquired
tissue for pathology and molecular profiling,
sonobiopsy has the potential to become the third
pillar for brain tumor management by substantially
advancing brain cancer diagnosis, treatment
monitoring, and recurrence detection. This enhanced
capability could have an important impact
throughout the continuum of patient care. In the early
diagnostic phase, sonobiopsy could rapidly determine
the molecular profile of suspicious lesions observed
on neuroimaging scans without the need for surgery.
ctDNA has been identified as a promising biomarker
for brain cancer diagnosis. The DNA alterations that
drive cancer progression, including mutations, copy
number changes, and modifications in key driver
genes, are detectable in ctDNA [86]. By understanding
the genetic alterations early, the cancer can be more
effectively managed. There is a reported specificity
>99% to distinguish cancer patients from healthy
individuals [87,88]. Technical improvements of
analytical approaches may lower the limit of detection
to identify mutations with allele frequency as low as
0.1% [89–91]. Despite these metrics that make ctDNA
a promising early diagnosis biomarker, the main
limitation preventing the use of ctDNA for early
diagnosis is that early-stage tumors have a low
disease burden and do not shed enough ctDNA
[75,86,92]. This poor sensitivity (43–50% for stage I
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non-brain cancers using CancerSEEK [88] or
CAPP-Seq [93]) is the motivation for sonobiopsy. By
improving the sensitivity for ctDNA, sonobiopsy may
be the missing key to enable early diagnosis with
ctDNA, In a mathematical model of plasma biomarker
kinetics, Hori and Gambhir showed that a tumor can
grow unnoticed for more than 10 years before it is
detectable by current clinical blood assays [94].
However, if the biomarker shedding rate, i.e., the
number of biomarkers entering the blood circulation,
was increased 1000-fold (similar to the 920-fold
increase of EGFRvIII ctDNA), the detection time
reduces to 5 years. This would be crucial for clinicians
to diagnose early-stage tumors and initiate treatment
to improve progression-free survival and quality of
life. Future studies will be performed to investigate
the correlation between tumor volume and
sonobiopsy sensitivity to demonstrate the capability
of sonobiopsy in early-stage cancer diagnosis. In the
treatment phase, sonobiopsy could also enable
repeated longitudinal sampling to monitor treatment
response. Though surgical tissue biopsy is the gold
standard to sample a tumor’s genetic information
[14,75], it can only be performed once or twice
because of the surgical risk associated with
intracranial surgery. This precludes the routine
interrogation necessary to evaluate treatment
response. Cerebrospinal fluid (CSF) is an alternative
LBx sampling method that has higher sensitivity than
blood LBx [95]. However, the invasiveness of repeated
CSF sampling, which raises safety concerns and the
potential risk for developing serious adverse effects in
some patients with brain tumors, such as increased
intracerebral pressure, may preclude the utility of
CSF-based LBx [96]. Moreover, CSF-based LBx may
not be feasible for tumors with limited DNA shedding
to the CSF (e.g., brain tumors that do not contact a
CSF compartment or ventricular space) [97]. By
enriching the blood with brain tumor-derived
biomarkers, sonobiopsy could potentially enable the
sensitive molecular characterization of brain cancer
for longitudinal clinical monitoring. In the
post-treatment phase, sonobiopsy could provide
complementary information in situations where
assessment based on neuroimaging alone remains
challenging (e.g., differentiating treatment-induced
pseudoprogression from true relapse) [14,98]. In
addition, sonobiopsy also could support the
investigation of tumor-specific molecular mechanisms
driving diseases and accelerate the development of
effective therapeutic approaches for brain cancer.

Materials and Methods
All animal procedures were reviewed and
approved by the Institutional Animal Care and Use
https://www.thno.org
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Committee at Washington University in St. Louis in
accordance with the Guide for the Care and Use of
Laboratory Animals and the Animal Welfare Act.

Tumor cell preparation
The U87-EGFRvIII+ cells were kindly provided
by Dr. Frank Furnari from the University of
California-San Diego [99]. U87 cells also harbor the
TERT C228T mutation [100]. U87-EGFRvIII+-ZsGreen+
cells, used for CTC detection, were generated by
transduction of U87-EGFRvIII+ cells with the lentiviral
construct pCRoatan that contains ZsGreen cDNA
[101]. Both cell lines were cultured as an adherent
monolayer in DMEM supplemented with 10% fetal
bovine serum, 2 mmol/L l-glutamine, and 100
units/mL penicillin. They were maintained at 37°C in
a humidified CO2 (5%) atmosphere and the medium
was changed as needed. Prior to implantation, cells
were dispersed with a 0.05% solution of
trypsin/EDTA and adjusted to concentrations needed
for tumor implantation. Approximately 3×106 cells for
each tumor were implanted in pigs.

Mouse model of GBM
Immunodeficient mice (strain: NCI Athymic
NCr-nu/nu, age: 6–8 weeks, Charles River
Laboratory, Wilmington, MA, USA) were used to
generate the xenograft GBM model [47]. Briefly, mice
were anesthetized and the head was fixed on a
stereotactic device for injection of the tumor cells.
Cells were injected and the tumor growth was
monitored using a dedicated 4.7T small animal MRI
system (Agilent/Varian DirectDriveTM console,
Agilent Technologies, Santa Clara, CA, USA). Starting
at 7 days and continuing every 3 days thereafter, MRI
scans were acquired to monitor tumor growth and
changes in neuroanatomy. Further information is
provided in the supplementary information.

FUS setup and sonobiopsy procedure for mice
The MRI-compatible FUS transducer (Imasonics,
Voray sur l’Ognon, France) was made of a 7-element
annular array with a center frequency of 1.5 MHz, an
aperture of 25 mm, and a radius of curvature of
20 mm. Transducer details were previously described
[102] and are provided in the supplementary
information. Briefly, the axial and lateral full width at
half maximums (FWHM) of the FUS transducer were
5.5 mm and 1.2 mm, respectively. Pressure values
were derated to account for the 18% mouse skull
attenuation [103]. A catheter was placed in the mouse
tail vein for intravenous injection.
Coronal and axial T2-weighted MRI scans were
acquired to image the mouse head and locate the
geometrical focus of the transducer (same parameters
as aforementioned T2-weighted sequence used to

372
monitor tumor growth). The MRI images were
imported to a software program (ThermoGuide,
Image Guided Therapy, Pessac, France) to locate the
focus of the transducer via 3-point triangulation. The
transducer was moved to the tumor center for FUS
sonication. A pre-FUS axial T1-weighted MRI scan
was performed to visualize the tumor-induced BBB
permeability (same parameters as aforementioned
T1-weighted sequence used to monitor tumor growth)
after intravenous injection of MR contrast agent
gadoterate
meglumine
(Gd-DOTA;
Dotarem,
Guerbet, Aulnay sous Bois, France) at a dose of
1 mL/kg diluted 1:1 in 0.9% saline.
Definity microbubbles (Lantheus Medical
Imaging, North Billerica, MA, USA) at a dose of 100
µL/kg were injected intravenously to the mice, as
determined by the prior parameter optimization
study (Supplementary Figure S1). FUS sonication
started 15 seconds prior to microbubble intravenous
injection (frequency: 1.5 MHz, pressure: 1.0 MPa,
pulse repetition frequency: 5 Hz, duty cycle: 3.35%,
pulse length: 6.7 ms, treatment duration: 3 min). FUS
sonication was performed at 3 points, evenly spaced
apart by 0.5 mm, to enable coverage of the entire
tumor volume.
After sonication, Gd-DOTA was re-injected and
a post-FUS axial T1-weighted MRI scan was
performed (same parameters as pre-FUS T1-weighted
sequence) to quantify the FUS-induced changes in
BBB permeability.

Porcine model of GBM
Pigs (breed: Yorkshire white, age: 4 weeks, sex:
male, weight: 15 lbs., Oak Hill Genetics, Ewing, IL,
USA) were implanted with the tumor cells on day 0
with an established protocol [66,67]. After the pig was
sedated by the Veterinary Surgical Services at
Washington University, the head was shaved,
prepared for sterile surgery, and immobilized in a
stereotactic frame on the operating table. The bite bar
and ear bars were positioned to secure the head such
that the top of the skull was level with the operating
table. A 2–3 cm midline cranial skin incision was
made and two 5 mm burr holes were drilled 5 mm
posterior from bregma and 7 mm to the subject's right
and left from midline without breaking the dura
(Dremel, Racine, WI, USA). A 50 µL syringe
(Hamilton, Reno, NV, USA) used for tumor cell
injection was fixed on the stereotactic frame and
positioned in the burr hole with the tip at the dura.
The syringe was lowered 9 mm to the injection site
and the Micro4 controller (World Precision
Instruments, Sarasota, FL, USA) infused 40 µL with a
rate of 44 nL/sec. There was a 5-minute delay
between infusion completion and needle withdrawal
https://www.thno.org
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to allow the cells to settle in the tissue and prevent
backflow. The burr holes were filled with gel foam
and the skin incisions were closed with two layers of
sutures. A cyclosporine oral solution (Neoral,
Novartis Pharmaceuticals, East Hanover, NJ, USA)
was administered (25 mg/kg) twice daily via gavage.
Seven days post-surgery, a contrast-enhanced
sagittal T1-weighted gradient echo MRI scan (TR/TE:
23/3.03 ms; slice thickness: 0.9 mm; in-plane
resolution: 0.94×0.94 mm2; matrix size: 192×192; flip
angle: 27°) was acquired on the 3T Siemens PRISMA
Fit clinical scanner (Siemens Medical Solutions,
Malvern, PA, USA) to validate tumor growth. An
intravenous catheter was placed in the ear for ease of
microbubble and gadolinium injections. During the
treatment and MR scans, a pulse oximeter (Nonin
7500FO, Plymouth, MN, USA) monitored blood
oxygen levels and pulse rate, while heated blankets
were used to regulate the temperature.

FUS setup and sonobiopsy procedure for pigs
A customized MRI-guided FUS device and an
established FUS procedure was used for successful
BBB disruption [48]. The pig head was fixed in a
stereotactic head frame with a bite bar and head
supports and coupled with the transducer. The FUS
system (Image Guided Therapy, Pessac, France)
included an MR-compatible 15-element transducer
with a center frequency of 650 kHz, an aperture of
65 mm, and a radius of curvature of 65 mm, and an
adjustable coupling bladder. The FUS system was
attached to an MR-compatible motor for enhanced
targeting precision. The FUS transducer calibration is
provided in the supplementary information. Briefly,
the in vivo acoustic pressure was estimated with the
top portion of a harvested ex vivo pig skull. The axial
and lateral FWHM of the transducer was 3.0 mm and
20.0 mm, respectively.
FUS was performed under MR guidance of the
1.5T Philips Ingenia clinical MR scanner (Philips
Medical Systems, Inc., Cleveland, OH, USA). Coronal
and axial T2-weighted spin echo MR images were
acquired to examine the neuroanatomy for treatment
planning (TR/TE: 1300/130 ms; slice thickness:
1.2 mm; in-plane resolution: 0.58×0.58 mm2; matrix
size: 448×448; flip angle: 90°). Coronal and axial
T2*-weighted gradient echo MR scans were used to
visualize the presence of air bubbles in the acoustic
coupling media (TR/TE: 710/23 ms; slice thickness:
2.5 mm; in-plane resolution: 0.98x0.98 mm2; matrix
size: 224x224; flip angle 18°). The FUS targeting was
performed with the same ThermoGuide workflow as
the mouse sonobiopsy. Gadobenate dimeglumine
(Gd-BOPTA; Multihance, Bracco Diagnostics Inc.,
Monroe Township, NJ, USA) was intravenously
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injected at a dose of 0.2 mL/kg and an axial
T1-weighted ultrafast spoiled gradient echo MR scan
was acquired as a pre-FUS baseline (TR/TE: 5/2 ms;
slice thickness: 1.5 mm; in-plane resolution:
0.68x0.68 mm2; matrix size: 320x320; flip angle 10°).
Definity microbubbles (Lantheus Medical
Imaging, North Billerica, MA, USA) at a dose of
20 µL/kg were injected intravenously. FUS sonication
started 15 seconds prior to microbubble intravenous
injection using the following parameters: frequency:
0.65 MHz, pressure: 3.0 MPa, pulse repetition
frequency: 1 Hz, duty cycle: 1%, pulse length: 10 ms,
treatment duration: 3 min. The bolus injection was
determined by the precedence set by the clinical
papers that have a similar injection paradigm
[45,68,69,104] and the observation that the contrast
enhancement via bolus is greater than the
enhancement via infusion [105]. The 3-minute
sonication was previously determined as the time
point when all the microbubbles were depleted, as
observed by a lack of stable cavitation during passive
cavitation detection. The treatment was repeated at 4
individual points spaced 3 mm apart to ensure
coverage of the tumor.
After FUS sonication was completed, Gd-BOPTA
was intravenously injected and an axial T1-weighted
MR scan was acquired (same parameters as the
pre-FUS T1-weighted sequence) to assess the BBB
permeability. Coronal T2*-weighted images were
acquired (same parameters as pre-FUS) to assess the
potential for FUS-induced tissue damage.

Mouse and pig plasma isolation
Mouse whole blood (~500 µL) was collected via
cardiac puncture and pig whole blood (~10 mL) was
collected via percutaneous catheter within peripheral
vessel using BD Vacutainer K2 EDTA tubes (Becton
Dickinson, Franklin Lakes, NJ, USA). Within 4 hours
of collection, samples were centrifuged at 3000×g for
10 minutes at 4°C to separate the plasma from the
hematocrit. Plasma aliquots were put on dry ice
immediately for snap freezing and stored at -80°C
subsequently for later downstream analysis.

Cell-free DNA extraction and quantification
Plasma/Serum RNA/DNA Purification Mini Kit
(Norgen Biotek, Thorold, ON, Canada) and
Plasma/Serum
cfc-DNA/cfc-RNA
Advanced
Fractionation Kit (Norgen Biotek, Thorold, ON,
Canada) were used to extract cfDNA from mouse and
pig plasma per manufacturer's protocol. cfDNA were
eluted in 20 µL of each corresponding buffer and were
quantified using Qubit Fluorometric Quantitation
(Thermo Fisher Scientific, Carlsbad, CA, USA). The
2100 Bioanalyzer (Agilent Technologies, Palo Alto,
https://www.thno.org
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CA, USA) was used to assess size distribution and
concentration of cfDNA extracted from plasma
samples. The total cfDNA concentration was
determined with the software as the area under the
peaks in the mononucleosomal size range (140–230
bp).

Cell-free DNA pre-amplification
An initial preamplification reaction was run
prior to ddPCR in the case of very low DNA
concentration. cfDNA were pre-amplified using Q5
hot start high-fidelity master mix (New England
Biolabs, Beverly, MA, USA) with forward and reverse
primer pair for EGFRvIII and TERT C228T (same
primers used for ctDNA analysis). Pre-amplification
was performed with the Eppendorf Mastercycler:
98°C for 3 min; 12 cycles of 98°C for 30 s, 60°C for
1 min; a final extension of 72°C for 5 min, and 1 cycle
at 4°C infinite. Preamplified products were directly
used for further ddPCR reactions.

Plasma ctDNA analysis with ddPCR
Custom
sequence-specific
primers
and
fluorescent probes were designed and synthesized for
EGFRvIII and TERT C228T detection (Sigma Aldrich,
St. Louis, MO, USA). The forward and reverse primer
sequences for EGFRvIII are 5'-GGCTCTGGAGGA
AAAGAAAGGTAATT-3' and 5'-CCTTCGCACTTC
TTACACTTGC-3', respectively. The EGFRvIII probe
sequence is 5'-CAGATCACGGCTCGTGCGTCCGA
GCC-3' with the 6-carboxyfluorescein (6-FAM)
fluorophore and the Black Hole Quencher 1 (BHQ1).
The forward and reverse primer sequences for
EGFRwt are 5'-TCTCAGCAACATGTCGATGGAC-3'
and 5'-AGTTCTCCTCTCCTGCACC-3', respectively.
The EGFRwt probe sequence is 5'-CTCCC
ATTGGGACAGCTTGGATCACAC-3' with the hexachlorofluorescein (HEX) fluorophore. The forward
and reverse primer sequences for TERT C228T mutant
are 5’-CGTCCTGCCCCTTCACCTTC-3' and 5’-GCAG
CGCTGCCTGAAACTCG-3', respectively. The TERT
C228T mutant probe sequence is 5'-CGTC
CCGACCCCTTCCGGGT-3' with 6-FAM and BHQ1.
The forward and reverse primer sequences for TERT
C228T wild type are the same as those for TERT
C228T mutant. The TERT C228T wild type probe
sequence is 5'-CGTCCCGACCCCTCCCGGGT-3' with
HEX and BHQ1.
ddPCR reactions were conducted using Bio-Rad
Q200X according to the manufacturer's instructions
(Bio-Rad, Hercules, CA, USA). ddPCR reactions were
prepared with 2× ddPCR Supermix for probes (no
dUTP) (Bio-Rad, Hercules, CA, USA), 2 µL of target
DNA product, of 0.1µM forward and reverse primers,
and of 0.1µM probes. For TERT C228T reaction mix,

374
100µM 7-deaza-dGTP (New England Biolabs, Beverly,
MA, USA) was added to improve PCR amplification
of GC rich regions in TERT promoter. The QX200
manual droplet generator (Bio-Rad, Hercules, CA,
USA) was used to generate droplets. The PCR step
was performed on a C1000 Touch Thermal Cycler
(Bio-Rad, Hercules, CA, USA) by use of the following
program: 1 cycle at 95°C for 10 min, 48 cycles at 95°C
for 30 s and 60°C for 1 min, 1 cycle at 98°C for 10 min,
and 1 cycle at 12°C for 30min, 1 cycle at 4°C infinite,
all at a ramp rate of 2°C/s. All plasma samples were
analyzed in technical duplicate or triplicate based on
sample availability. Data were acquired on the QX200
droplet reader (Bio-Rad, Hercules, CA, USA) and
analyzed using QuantaSoft Analysis Pro (Bio-Rad,
Hercules, CA, USA). All results were manually
reviewed for false positive and background noise
droplets based on negative and positive control
samples. Assays were considered positive if >3
droplets exceeded the threshold fluorescence
[106,107]. Otherwise, the specimen was determined to
have 0 copies/µl. EGFRvIII and TERT C228T ctDNA
concentrations (copies/µl plasma) were calculated by
multiplying the concentration (provided by
QuantaSoft) by elution volume, divided by the input
plasma volume used during DNA extraction. A
subject had a positive detection of the mutation when
the levels of mutant ctDNA were >0 copies/μL. The
EGFRvIII and TERT C228T sensitivities were
calculated as the true positive rate, i.e., number of true
positives divided by the sum of true positives and
false negatives. The 95% confidence intervals were
calculated according to the familiar, asymptotic
Gaussian approximation 1.96√p(1-p)/n, where p
represents sensitivity and n was the sample size
[108,109].

MRI analysis
MRI processing and analysis was performed
using a custom MATLAB script as previously
described [48]. Further information is provided in the
supplementary information.

Histological analysis
After blood collection, mice were transcardially
perfused with 0.01 M phosphate-buffered saline (PBS)
followed by 4% paraformaldehyde. Brains were
harvested and prepared for cryosectioning. Pig brains
were harvested and fixed in 10% formalin. The brains
were horizontally sectioned to 15 μm slices and used
for H&E staining to examine red blood cell
extravasation and cellular injury or TUNEL staining
to evaluate number of apoptotic cells. The brain slices
were digitally acquired with the Axio Scan.Z1 Slide
https://www.thno.org
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Scanner (Zeiss, Oberkochen, Germany). QuPath v0.2.0
[110] was used to detect areas of microhemorrhage
and TUNEL expression. The imaged slice for mouse
histological analysis was segmented into the tumor
region of interest (ROI) that includes the tumor mass
and extends 0.5 mm into its periphery, which is
consistent with the safety objectives from previous
studies [111] and the potential damage caused by the
external and lumen diameters of a biopsy needle
[112,113]. The parenchyma ROI was defined as the
whole imaged slice without the tumor ROI. The tumor
ROI for the histological analysis in pigs included the
tumor mass and a 3 mm margin [114].
After color deconvolution (hematoxylin vs.
eosin), areas of microhemorrhage were detected using
the positive-pixel count algorithm. The microhemorrhage density was calculated as the percentage
of positive pixel area over the total stained area in the
respective ROI. The number of apoptotic cells were
detected using the positive cell detection algorithm.
The TUNEL density was calculated as the percentage
of positive cells over the total stained cells in the
respective ROI.

Statistical analysis
To analyze significance across multiple
comparisons, the Kruskal-Wallis test and post hoc
Dunn's test with Bonferroni correction was performed
(Figure S1A–F, H, and I). Where appropriate, the data
was analyzed with the paired samples Wilcoxon
signed rank test (Figure 1C, 4D, 5B, and 5D) or the
unpaired two-sample Wilcoxon signed rank test
(Figure 2B, 2D, 3B, 3D, 6B, 6D, and S2B). The
correlations between biomarker release, contrast
enhancement, and tissue damage were evaluated with
the Pearson correlation test. Statistical differences
were considered significant (*) when p < 0.05, (**) when
p < 0.01, (***) when p < 0.001, and (****) when p < 0.0001.
Descriptive statistics is represented as mean ± SD.
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